and November. performance We're issued expected, better that guidance share with Todd, the fourth good yielding non-GAAP quarter year in higher per than morning. we you, than end slightly to earnings that and Thank annual revenue pleased was a
we environment, details last with biopharmaceutical in including our XXXX market demand results, update. more our update provide restructuring can trends expect remains our clients KPIs, guidance. activities and compared the update an many will I consistent say ratio our on the early-stage demand stable I constrain by book-to-bill DSA clients on of throughout net continue view to financial trends was forward Beginning the our biopharmaceutical again these of the similar third expected and in to I with an spending move pipeline that market reprioritization quarter of XXXX. with provide quarter are which Many to fourth Overall, XXXX. Before the global on
trends to mid-sized X the end biotechnology the and to last from slightly more continued to compared of we funding DSA flattish combined Small clients years, in benefit environment previous within to improved XXXX demand in These stable result a XXXX. will XXXX be are biotech demand versus and sequentially favorable expect through expected trends year.
be a the their clients we of year. lower in at study global However, last expect budgets volume in many reset level biopharmaceutical because XXXX to than middle
monitoring patterns, years measured. closely XXXX biotech R&D has well environment spending which of believe as for our couple We're slowed as new the are company the clients' past funding over expectations rates appropriately and our interest and formations,
are as the at in influencing follows. investor a primary XXXX outlook As discussed factors conference, recent our
well relates for anticipated first XXXX, in expectation from The headwind DSA our DSA year. throughout as as to environment the demand pricing stabilizing lower an
to including year. X%. factors And by actions X.X% by commercial consolidated revenue is this in organic which are when reduce points result these is of expected revenue consolidation a basis basis this year. additional our the approximately X.X% headwind CDMO of in to revenue finally, will in site to an lower And of of The expected over The item business, effect revenue decline XXXX. revenue XX second X% reduce exchange a foreign on cumulative X%, an a reported to decline X.X%
yield to including will value, protect year. taken $XXX XXXX, We are action approximately realized over annualized be million savings $XXX the restructuring million of operating margin shareholder significant and initiatives this to of expected have in that which
fully be offset decline range a will non-GAAP share operating expected margin per able XXXX, $X.XX modestly in not is of we result the lower However, and $X.XX. DSA particularly revenue consolidated to a in to segment, in earnings in which the to the
I'd year on recap billion our the to an previous XXXX, fourth from the revenue basis fourth organic Now quarter of X.X% in like year. performance. quarter quickly reported decline of We full and consolidated $X a
revenue For the by year, billion revenue DSA lower revenue. primarily decrease of reported driven organic $X.XX with X.X%, we of an
fourth Our for the and and global range provided revenue segment performance that Sales we small quarter biopharmaceutical client a the midsized in biotech in of robust November, to fourth full see biotech year pleased growth the the the since were the Solutions. quarter first quarter, outperformed year-end But full to for and the Microbial time XXXX. year. from for clients we revenue a third better-than-expected RMS segments return slightly in led both declined by to
XX.X% also the points the lower and limit segments. the driven expansion quarter, RMS to margin DSA to operating segment. basis and manufacturing declines helped costs cost-saving in XX by The fourth margin corporate initiatives increased the The principally margin unallocated year-over-year in in
XXXX. an DSA full the points increase fourth higher unallocated Earnings decrease segment and costs. interest fourth per rate quarter as $X.XX in driven was year, XX $X.XX declined led in expense, the were primarily the XX.X%. quarter, by fourth operating reductions earnings as operating For to basis items, The in below-the-line as of including margin corporate of well share the count improvement. to X.X% the tax by margin well The from share the favorable quarter the as expansion
XXXX, to margin, $XX.XX of initiatives. saving operating by offset primarily cost the by partially For due to the and declined revenue benefit X.X% per lower earnings share
well provide was revenue I'll in of as volume outlook performance. on The quarter Turning X.X% fourth slightly reflected lower basis. an to on DSA segment's the lower decrease as each now fourth with million, pricing. additional segment you for a quarter $XXX.X decline the study organic XXXX. details and
as during XXXX environment pricing the fourth work Assessment started pricing As from anticipated, in to stream. revenue into Safety the turned moderating negative backlog the quarter
small In the point current midsized demand clients, become with and particularly biotechs. discussion has environment, pricing a of
has client as utilized have pricing and an book-to-bill the fourth the the commercial capture stable improved net our believe with enhancements, during with rate, DSA demonstrated to share -- were in integration by of sales including been We rate including cancellation DSA demand successful better gain force the and strategy selectively DSA XXXX. also other goal KPIs additional a following strategically ratio that and quarter, global the and trends market quarter the net to was this the global global continue third divergence biopharmaceutical with second a in the resulted remained fourth midsized down in with XXXX, impact in the second Xx quarter XXXX. range, the biopharmaceutical book-to-bill and step small quarter biotech of segments similar below and revenue taking clients to will during half which a in in consistent
not in priority our most lower revenue in canceling backlog year that levels. have as which will the programs the remain quarter occurred. improvement growth have to segment a process that key largely so the the for of at levels closer remained sustained in fourth DSA and lower be to yet targeted activity, for to will of completed has they booking the the also Cancellations return past We believe clients
outlook DSA quarter. DSA an the declined the single-digit X.X% to year, $X.XX billion our in revenue our basis, with be a third backlog previous revenue year-end, was decline. favorable from of full which November on would $X.XX at -- to organic At end expectation consistent the decreased DSA high the that For in billion modestly the of
slightly at a will decline In XXXX. expect organic XXXX, favorable less an on rate mid- will revenue be DSA which we high in single-digit than to basis
steady expect both We decline. a will lower that on volume XXXX similar pricing the have and impact
from for sequentially global segments, relatively biopharmaceutical level volume but and As due biotech the a primarily will than XXXX second to of emerged in softer I in expect mentioned the the throughout biopharmaceutical last global we earlier, that at half study clients year. XXXX, lower be stable demand client
XXXX in essentially pricing was not full addition, lower incremental when DSA the year. in pricing an XXXX will In that realized present realized headwind for flat was add
relatively the in a demand impact in first during the not DSA the We year, meaningful the should seasonal of XXXX of be environment gaiting over course from have at DSA quarterly revenue quarter. consistent dollars time this any assumed modest for aside improvement the
a enact an international CITES, weeks, in from the once on very of has made trade the recent trade supply pleased studies recent sustain of We biomedical postponed again trade that used until animals, February the in the the NHP agenda item a of proposal meeting as oversees result potentially year. not research and did at headlines In early body of Standing Committee the NHPs, suspension to end the this including meeting at NHPs of matter the that Cambodia. were
and accurate fair, a for being on facts time the this support strong community's review international contract the review underscores to providing decision by the disseminated This process other groups. and science-based information necessary
agencies, River that human advanced consequences drug will development industry models do currently believes safety critical and Charles continue any and the for clear. educate the when with not partners to safety help patient regulatory NHPs, could be trade impact government firmly unintended will particularly me action from of patient research NHPs NHPs are required our clients significant about River biomedical associations viable availability scientific the global Legally biologics to purpose-bred that have of biopharmaceutical and Cambodia sourced importance globally. to Let ensure restrict and officials, promote biopharmaceutical work our to collaboratively industry. regulatory Charles alternatives exist.
of diligently interest and procuring arrangements the With outside supply Noveprim regard we will to through continue in our Cambodia, various in chain to controlling our secure diversify NHPs Mauritius. work including and our NHP supply, by supply to
will of As we in utilize Mauritius a DSA increasing after our to reminder, segment XXXX. NHPs number be an able
were for decline the margin XXXX, and was was point updated partially appendance In a representing of NHP and XXX basis year from DSA by fourth included revenue from lower XXX fourth for XX.X% XX.X% report point savings. have we which slide our were quarter offset driven was XXXX presentation key a last or XXXX, year-over-year. the declines basis full that year. of full by operating cost certain the today, Both statistics year fourth benefit our quarter in in also the the decrease primarily the quarter of
the on revenue fourth basis. was an X.X% $XXX.X of a organic RMS decrease in quarter million,
was RMS revenue just flat decline a year, essentially with organic on an basis. X.X% the For
services, small higher in in revenue including quarter models principally lower the was in higher all sales NHP Cell driven the year, model research China by both the geographic For CRADL, by mostly for regions, offset Solutions pricing. sales research business and of
volume was by driven European and American XXXX higher for to for higher growth low research Solutions pricing to NHP site. rate, consolidation single-digit a from environment. the increase fatal to models in its research due RMS part rate revenue third-party models at growth improved Unit Cell impacted California largest continued operations and North small XXXX including in primarily businesses, XXXX, the of to large its spending prospects model the is clients. in lower sales biopharmaceutical Noveprim be by expected to softer services
However, higher unit these higher from pricing institutions and academic more declines. than revenue offset volume
more trends Europe We unit pricing in in expect than higher XXXX and offsetting North lower similar America with volumes.
in the expect small also flattish challenged. We be to sciences continues somewhat revenue China life as to environment be models
monitor Given news NIH funding, and government closely of the health our the recent base. client around academic we will
exposure the related our contracts. NIH largely solutions X% to total represents less direct Our of to revenue, than in-sourcing
costs these are clients. significant offset year, direct impact as revenue revenue but to indirect monitor and RMS in For Overall, projects anticipated third-party growth consider the models this revenue are will components in lower critical research NIH's academia, NHP research any, to large on academic not to will we models will China. small partially new if costs, cap directive what, Noveprim's have research increase to by NHP a be contributor be expected
and notable research in for Demand to RMS rebound is model revenue XXXX. become expected contributor for services growth a
sites utilize track increasingly Moderate new Our is dedicated by performance efforts sites services new improved complex support driven tighter their growth to these research to either environment, or limit this back top line CRADL of risk expected to to XXXX, in genetically model primarily and operations will deliver budgetary in maintenance GEMS modified anchor is on expected clients. business get the have as the colonies. of CRADL clients an
increased access clients proposition powerful to are in Clients without are attractive to having provides for by margin infrastructure, vivarium to basis year-over-year in which fourth invest continuing points reduce operating points view to to to a space model RMS decreased The costs CRADL as the by conserve but looking who basis and XXXX. value in XX.X% XX an internal quarter flexible capital. XX XX.X%
our small related for sales higher the to related to NHPs the For primarily the restructuring revenue acquisition. cost year, was Noveprim mix to margin savings pricing initiatives and operating research due due favorable of higher improvement models, to a
We the operating margin drivers RMS expect XXXX. to in to similar contribute
year-end Manufacturing organic organic rate offset The million growth lower was the performance commercial fourth $XXX.X Solutions X.X% and growth growth on organic quarter, robust in the in rate testing by XXXX flat Microbial in drivers fourth revenue an XXXX will that projects repeat, revenue business, basis, was rate an X.X%. Solutions same rate in client quarter growth was of essentially on the in result a slower primarily for by full XXXX. will These in certain year in basis. the CDMO from driven moderated a revenue result which likely benefited business. manufacturing Biologics will not
efforts will XXXX the consolidated rate enhance clients investor at through a facilities, in by X more expect for CDMO foundation we established investments and X%. past recent the growth believe to segment's in approximately scientific CDMO mentioned the the years than lower Despite As from commercial and operations by commercial revenue a X% revenue Manufacturing we this our expertise. have conference, over solid reduce leadership setbacks, business X
our move of strong Microbial clients as and the to growth year-end gene the as we increasingly testing products testing manufacturing, clinical quality for to Endosafe rapid have across utilizing believe we with as acquired not testing quarter business Accugenix. ready strong to in for help the that the when reported their with enhance in all demand testing as microbial consumables efficiency. cell we growth with business X instrument robust a and the demand has was XXXX, release, is long-term demonstrated solid and healthy way The biotech forward. it believe control, and Although placements. and continued are lead speed rebounded attractive clients the sector another Celsis exist We pipeline the thoroughly Endosafe, product Solutions performance candidates opportunities growth platforms, comprehensive, performance early-stage business solutions robust well a XXXX CDMO
operating was in We XX.X% from Manufacturing The by margin driven quarter to to the the points by XX.X% increased basis full the expansion, margin for basis leverage Microbial XXX demand by year. improved by were which operating fourth segment's points pleased in XXX the and operating Solutions manufacturing XX% including businesses to its level remains couple our goal on and CDMO. margin across focus generating all track businesses, continued Biologics operating We believe on the within reach return Testing an and greater the of a segment efficiencies to above to years.
constrained currently To continued a environment challenging operating conclude, we in we are biopharmaceutical demand believe spending, but trends client demand that stabilizing. with are
On the favorably. biotech is side, positive trending
seen further have global of biopharmaceutical clients. deterioration not from signs We our
forecasting not XXXX. in recovery we're However, a
X% the action costs structure. including We and current shareholder protect generate to environment, appropriately to are decisive manage revenue, taking and initiatives our over cost committed eliminating contain value. through We company infrastructure rightsizing our to remain of more the
X efficiency; other demand; with initiatives main levels staffing global streamlining manage and actions generate and To these greater in costs ensure by progress our and restructuring align to we reducing operations. areas: of to to make the our success, pace strategic continue on footprint future optimizing processes and
on these We million selectively have made from generate to cost meaningful and efficiency front and of additional this continue now costs evaluate and progress initiatives. $XXX savings opportunities expect drive cut approximately to annualized to
focus client-centric market and is concentrating promote share. on gain area commercial to a second enhancements The additional
e-commerce reinforce our role partner leveraging is goal clients, client to as such Apollo Our initiatives. our and RMS flexible through and the our and enhance our experience platform including to responsive technologies a as
us finally, force are have we earlier, mentioned past and pricing capital. sales approach to taking regularly balanced our enabled revisiting over allocation, dynamic uses and market capital to And the our gain best to I year. a share strategy our enhancements As DSA for
with as We repurchase to allocate are it we and remains or intend goal our we awards. most equity we that our $XXX last is opportune to our undervalued, coupled to our initial stock M&A year XXXX Based stock done, our the next from exceeds cash And continue of offset annual very routinely dilution over leverage low evaluate an this in the to pleased capital belief billion low anticipated that million select million year time needs have are Xx range. currently candidates. X, We to our free $X of flow which under approximately authorization. month in $XXX repurchases in on
an stronger, We to and have responsive navigated even and more leaner profitable our company will before, we challenges actions this period more strategic a believe clients. us from partner emerge for our enable and
global thank extending preferred continued partner. their their We shareholders through and for development to exquisite work our I'd distinguished and drug leading clients' ourselves our employees exceptional our science have always nonclinical clients preclinical for as commitment position and focus, our support. our and like
XXXX details performance and Now Flavia provide will our financial on additional guidance.
